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Abstract
Nerve Growth Factor (NGF) augments excitability of isolated rat sensory neurons through
activation of the p75 neurotrophin receptor (p75NTR) and its downstream sphingomyelin signaling
cascade, wherein neutral sphingomyelinase(s) (nSMase), ceramide, and the atypical PKC (aPKC),
PKMζ, are key mediators. Here we examined these same receptor-pathways in vivo for their role
in mechanical hyperalgesia from exogenous NGF. Mechanical sensitivity was tested by the
number of paw withdrawals in response to 10 stimuli (PWF = n/10) by a 4g von Frey hair (VFH,
testing “allodynia”) and by 10g and 15g VFHs (testing “hyperalgesia”). NGF (500 ng/10 µl)
injected into the male rat’s plantar hind paw induced long lasting ipsilateral mechanical
hypersensitivity. Mechano-hypersensitivity, relative to baseline responses and to those of the
contralateral paw, developed by 0.5–1.5h and remained elevated at least for 21–24h, Acute
intraplantar pre-treatment with nSMase inhibitors, GSH or GW4869, prevented the acute
hyperalgesia from NGF (at 1.5h) but not that at 24h. A single injection of N-acetyl sphingosine
(C2-ceramide), simulating the ceramide produced by nSMase activity, induced ipsilateral
allodynia that persisted for 24h, and transient hyperalgesia that resolved by 2h. Intraplantar
injection of hydrolysis-resistant mPro-NGF, selective for the p75NTR over the TrkA receptor, gave
very similar results to NGF and was susceptible to the same inhibitors. Hyperalgesia from both
NGF and mPro-NGF was prevented by paw pre-injection with blocking antibodies to rat p75NTR
receptor. Finally, intraplantar (1 day before NGF) injection of mPSI, the myristolated
pseudosubstrate inhibitor of PKCζ/PKMζ, decreased the hyperalgesia resulting from NGF or C2-
ceramide, although scrambled mPSI was ineffective. The findings indicate that mechano-
hypersensitivity from peripheral NGF involves the sphingomyelin signaling cascade activated via
p75NTR, and that a peripheral aPKC is essential for this sensitization.
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Nerve growth factor (NGF) plays a critical role in development and growth of peripheral
sensory neurons, and also induces thermal and mechanical sensitization of these neurons in
adult mammals. Much evidence indicates that in adults NGF may still have some trophic
role, but its main function is to initiate and maintain nociceptor hypersensitivity as a part of
inflammatory and immune responses after tissue injury (see Pezet and McMahon, 2006).
The trophic actions of NGF have been attributed to activation of a receptor tyrosine kinase
(TrkA) that is expressed on peripheral and central neurons and distinguished by its high
affinity for NGF (Meakin and Shooter, 1992; Barker and Murphy, 1992; Fundin et al.,
1997). Nerve growth factor is also known to induce hypersensitivity and pain in humans
(Dyck et al., 1997; Svensson et al., 2003; Rukwied et al., 2010) and to decrease nociceptive
thresholds in rodent models of pain (Lewin et al., 1993; Woolf et al., 1994; Woolf 1996;
McMahon et al., 1995; Hathway and Fitzgerald, 2006; Mills et al., 2013)
Results of a recent study exploring the capacity of NGF to directly and acutely modulate the
excitability of isolated sensory neurons suggest that such actions follow activation of the low
affinity NGF-binding receptor, p75 neurotrophin receptor (p75NTR), which can trigger
activation of the downstream sphingomyelin signaling cascade (for review see Nicol and
Vasko, 2007; Zhang et al., 2012). Neutral sphingomyelinase(s) (nSMase), ceramide and the
atypical PKC (aPKC), PKMζ, are important effector molecules of this intracellular pathway.
In the present work we aimed to determine the contribution of these mediators of the
p75NTR signaling pathway to the nociceptive mechanical hypersensitivity produced by local
NGF administration in rats in vivo. The results show that the p75NTR is essential for this
response and that inhibition of nSMase, i.e., of ceramide liberation from sphingomyelin, and
inhibition of peripheral aPKCs have preventive actions on the development of NGF-
dependent mechanical hypersensitivity.
2.0 Experimental Procedures
Experiments were conducted in adult male Sprague-Dawley rats (235–330g). Rats were
housed in groups of 2 per cage under a 12:12 h dark-light cycle and were provided with food
and water ad libitum. Animals were experimentally treated and cared for in accordance with
the Guide for the Care and Use of Laboratory Animals (Guide, 1996) as reviewed and
approved by the Harvard Committee on Animals
2.1 Mechanical testing
Unrestrained rats were placed on an elevated plastic mesh floor (28 × 17.5 cm; 9.5 × 9.5mm
openings) and allowed to habituate for 25–40 min before initial testing. Paw Withdrawal
Frequency to mechanical stimulation was determined using calibrated von Frey hairs (VFH)
applied perpendicular to the plantar surface of a hind paw through spacing in the mesh. Each
VFH (4g, 10g and 15g) was applied 10 times for 3 sec, separated by a 3 sec interval. Testing
with the next VFH started ca. 8–10 min after the beginning of the testing with a previous
force. Testing started with a lowest force of 4g, and continued with increasing forces, with
all three forces tested with 10 probings in each test period. To avoid stress and to obtain
consistent responsiveness to the same force, the rats were habituated and tested on mesh
racks over 5–6 days before each experiment (training period). Withdrawal responses were
registered initially on the ipsilateral paw (IPSI) in 4 rats, then on the contralateral paw
(CLP), for each VFH. The number of paw withdrawals, n, occurring in response to 10
stimuli (range: n=0–10) was used to assess mechanical sensitivity, and graphed as Paw
Withdrawal Frequency (n) for each force.
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2.2. Injection procedures
NGF, GSH, C2-ceramide, GW4869 or its vehicle, alone or with NGF, were injected
subcutaneously (s.c.) in a 20 µL volume into the mid-plantar hind paw, 1 cm distal from the
heel. The non-selective atypical myristoylated pseudosubstrate inhibitor (mPSI; also known
as ZIP, Eichholtz et al., 1993; Thiam et al., 1999) was injected s.c. into the plantar surface
(40 µg/20 µL). Injections occurred under brief general anesthesia from inhalation of the
rapidly reversible agent sevoflurane (Abbott Labs, N. Chicago, IL, USA). After anesthesia
was discontinued, the righting reflex recovered in <30 sec for intraplantar (i.pl.) injection;
5–10 min later “normal” nocifensive responses (thresholds, latencies) could be assessed.
2.3. Chemicals
NGF-β (rat) (Sigma-Aldrich, St. Louis MO, USA) was made as a stock solution (100 ng/µL
of phosphate buffered saline (PBS: pH7.4)) and stored in 40 µL aliquots at −80°C. L-
Glutathione (GSH, Sigma-Aldrich) was dissolved in PBS immediately before each injection
(fresh made solutions for pre- and co-injections). Prior to the injection, NGF stock aliquots
were diluted (1:1) in PBS or mixed with GSH solutions (for co-injections) to the noted final
concentration of 50 ng/µL. A non-hydrolyzable mutated homologue of Pro-NGF, mPro-
NGF (Alomone Labs, Jerusalem, Israel) was reconstituted in PBS, then centrifuged at
10,000×g for 5 min to remove any undissolved particulates before paw injection. C2-
ceramide (Enzo Life Sciences, Farmingdale, NY) was dissolved initially as a 25 µg/µL
DMSO stock solution, stored at −80°C in aliquots, then diluted to 20 µg/10 µL DMSO
before the injection. GW4869 (Sigma-Aldrich) was dissolved in DMSO as a 2 mM working
solution, and aliquots were prepared under an inert gas (nitrogen) and stored at −80°C. The
atypical PKC pseudosubstrate inhibitor, mPSI (Calbiochem, USA; Enzo Life Sciences) was
dissolved immediately before the experiment, first in H2O to 5 µg /µL and then diluted 1:10
in PBS.
A polyclonal blocking antibody to rat p75NTR was generously donated by Prof. Louis
Reichardt (University of California, San Francisco); 20 µL volumes were injected into the
plantar paw surface 4 h before the injection of NGF or Pro-NGF. As a control for the
p75NTR blocking antibody, a rabbit IgG solution containing approximately the same total
protein was used ( rabbit polyclonal IgG; Abcam, MA USA).
2.4. Experimental design
NGF was injected s.c. into the plantar surface of the rat’s hind paw, always at a dose of 500
ng in 10 µL. To test GSH effectiveness against NGF-induced hyperalgesia, GSH was
delivered in either of two injection protocols. 1) Acute pre-treatment: the first injection
occurred at “15” (15–18) min prior to NGF and the second injection was delivered mixed
with the NGF. Two different dosing levels were delivered, one in which GSH was applied at
a low total dose (0.6 µmol/paw) and another at a high total dose (1.8 µmol/paw; the
concentrations and doses are indicated in the Results and figure legends). 2) Prolonged pre-
treatment: the first injection occurred 1.5h prior to the NGF injection, and the second, as in
(1), above, mixed with NGF. For these experiments, GSH was delivered at the high total
dose (1.8 µmol/paw). In Control experiments NGF-β (rat) was injected: 1) “15” (15–18) min
after the injection of the vehicle for GSH (PBS, 10 µl); 2) a single injection of GSH, without
NGF, was administered at a dose intermediate (1.2 µmol/paw) between the “high” and the
“low” total dose condition, which resulted in the highest concentration (120 mM) of GSH
used for either acute or prolonged pre-treatment.
To corroborate the effects of GSH, a structurally different nSMase inhibitor, GW4869 (2
mM, 10 µl) (or its vehicle) was injected once, either 17 min before or 1h after NGF.
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In another group of rats, membrane-permeant C2-ceramide alone, or its vehicle, was tested
for its ability to affect mechanical sensitivity after either a single i.pl. injection (20 µg/10 µl)
or following multiple injections of the same dose, spaced 75 min apart. This separation time
was chosen to be long enough to allow the acute, transient effects from a single dose to fully
reverse and therefore to minimize the role of a “sensitized state” in altering responses to
subsequent doses of the algogen.
To establish the importance of atypical PKCs (e.g., PKMζ) for NGF-dependent
hyperalgesia, a non-selective inhibitor of aPKCs, myristoylated pseudosubstrate inhibitor
(mPSI, 40 µg/20µL), or its vehicle, were injected s.c. into the plantar surface of the rat’s hind
paw. Such injection caused substantial edema, without accompanying changes in mechano-
sensitivity, but requiring a delay in the subsequent injection of NGF. The mean value for
each force was taken as the baseline paw withdrawal frequency at 1 day after mPSI
injection, when the paw size had returned to normal, shortly after which NGF was injected
into the paw.
2.5. Analysis
Data are presented as means ± S.E.M and evaluated using GraphPad InStat version 3.0
(GraphPad Software, CA, USA). Since the hind paw withdrawal frequency data presented
here do not follow a normal distribution, statistical analysis used nonparametric tests.
Friedman test followed by Dunn’s post hoc test was applied to compare repeated measures
of Paw Withdrawal Frequency with baseline values. An unpaired, two-tailed Mann-Whitney
U-test was used to compare responses, to the same force at the same time point, of the
ipsilateral and contralateral paws. Wilcoxon matched pairs (two-tailed) test, with repeated
measures correction, was applied for comparison of responses at different times with the
baseline response. P values <0.05 were considered to be significant.
3.0. RESULTS
3.1. NGF and C2-ceramide sensitize the paw to mechanical stimulation
Intraplantar injection of NGF (500 ng/10 µL) induced a long lasting ipsilateral mechanical
hyperalgesia. Paw withdrawal frequency for the 10g and 15g VFH, but not the 4g VFH, had
significantly increased by 0.5–1.5h after injection and remained elevated at 21–22h,
compared to either the baseline responses or the unchanged responses of the contralateral
paw (Fig. 1). (Responses to the 4g VFH varied among cohorts of rats and had the largest
variance, such that the changes after NGF sometimes reached significance but other times
did not. Changes in the response to the 15g VFH stimulation were consistent.) This general
pattern of a rapidly developing and persistent mechano-sensitization was observed
independently many times when NGF was injected into naïve paws.
A single injection of N-acetyl sphingosine (C2-ceramide, 20 µg/10 µL), a cell-permeant
ceramide analog, caused acute allodynia and hyperalgesia that, unlike that caused by NGF,
had usually resolved by 2h (Fig. 2A). In separate experiments, attempting to extend the
hypersensitivity by increasing the duration of C2-ceramide’s presence in the paw, three
sequential identical doses were injected, each 75 min apart, timed so that the effect from one
single dose had resolved before the next injection. This also caused an acute, ipsilateral
increase in mechanical responsiveness to stimulation with all three forces, one that was still
present at 2h after the last injection (Fig 2B), but had resolved by 24h (data not shown).
3.2. Antihyperalgesic actions of GSH
To further evaluate the role of the sphingomyelin cascade, we first tested whether inhibition
of nSMase, the enzyme catalyzing the liberation of ceramide, would suppress NGF-induced
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hyperalgesia. Acute pre-treatment with a semi-selective inhibitor of nSMase activation,
GSH (Liu and Hannun, 1997; Liu et al., 1998), pre-injected (120 mM, 10 µl) 15 min before
and then co-injected (60 mM, 10 µl) with NGF (total GSH dose = 1.8 µmoles/paw),
prevented significant acute mechano-sensitization at 1.5h but did not affect the increase in
mechano-sensitivity measured the next day (n=8) (Fig. 3A compare to Fig. 1A). Glutathione
applied at a lower total dose of 0.6 µmol (40 mM and 20 mM concentrations for pre- and co-
injections, respectively) did not attenuate NGF-induced enhancement of ipsilateral
mechanical responsiveness (n=8, data not shown). In contrast to the effects of immediate
pretreatment with GSH, when the higher pre-treatment dose (120 mM, 10 µl) was given 1.5h
beforehand followed by a co-injection of GSH (60 mM, 10 µl) with NGF, hyperalgesia was
not reduced, despite the high total dose of the inhibitor (n=4; Fig. 3B). In controls, injection
of GSH into the naïve paw, at a total dose (1.2 µmol; 120 mM, 10 µl) that was intermediate
between “high” and “low” doses, evoked swelling of the paw in 50% of rats by 3–4h, but
did not change mechanical responsiveness in either ipsilateral, or contralateral paws, as
compared to baseline values (n=4). Similarly, no changes in the mechanical responsiveness
were observed during the 1.5h pre-treatment of GSH, before the injection of NGF (n=8).
3.3. Attenuation of NGF-induced hyperalgesia by GW4869
Since GSH was used at a high concentration and affects many other proteins we examined a
more selective inhibitor of nSMase, GW4869 (Luberto et al., 2002; Marchesini et al., 2003).
This cell-permeant, non-competitive, nSMase inhibitor was injected into the paw 17 min
prior to NGF. The effect of this single application (2 mM, 10 µL; dose 20 nmoles) was
similar to the actions of the acute pre-treatment with high dose GSH; it prevented the
hypersensitivity at 0.5–1.5h, but not at 23h after NGF injection (n=8) (Fig. 4A). In the
vehicle control group, wherein NGF was injected following pre-injection of DMSO,
hyperalgesia developed as after NGF alone, both responses to 10g and 15g forces being
augmented significantly at 0.5–23h (n=8) (Fig. 4B). In neither group of rats were any
changes in responsiveness of the contralateral paw observed (data not shown). Therefore the
inhibitor of nSMase GW4869 prevented NGF-induced local mechanical hyperalgesia,
although this effect lasted less than one day.
Pre-injection of the paw with GW4869 had no effect on the acute hyperalgesia caused by the
C2-ceramide injection (n=8, data not shown). This result is consistent with an upstream
inhibition of GW4869, at the nSMase location, and also shows that the inhibitor did not alter
any reactions of the downstream pathway.
When GW4869 (2 mM, 10µL) was injected 1h after NGF it failed to reverse the already
developed mechanical hyperalgesia (n=7) (Fig. 4C). Some tendency to attenuate the
hyperalgesia was noticed at 35–50 min after injection of GW4869; the NGF-induced
increase in mechanical response to 10 and 15 g VFHs did not reach significance vs. baseline
in a group test (Friedman+Dunn’s). These changes vs. ipsilateral baseline, however, were
highly significant for 15 g VFH, when compared using the Mann-Whitney test (p=0.0006).
3.4. Hypersensitivity from Pro-NGF
A non-hydrolyzable homologue of Pro-NGF (Pagadala et al., 2006, the larger precursor to
mature NGF which has selectivity for the p75NTR over the TrkA receptor (Lee et al., 2001;
Beattie et al., 2002; Ibañez, 2002; Teng et al., 2010), also caused hyperalgesia. Injections of
this mPro-NGF (500ng/10µL) into the hindpaw increased responsiveness to 10 and 15 g
VFH at 0.5 to 21 h, very similar to the time-course following NGF injection (Fig. 5;
compare to Fig 1A). Responsiveness to the 4g VFH was not significantly changed.
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3.5 A p75NTR blocking antibody abolishes NGF-induced hyperalgesia
To further confirm that the active receptor for NGF’s actions is p75NTR, we used a receptor-
specific antibody. Polyclonal rat anti-p75NTR antibodies (generously donated by Prof. Louis
Reichardt, UCSF) were injected into the plantar hindpaw 4h before NGF or mPro-NGF
injection. The antibody alone did not affect mechano-responsiveness (Fig 6A). Subsequent
injection of NGF (Fig. 6A) or mPro-NGF (in separate experiments, Fig. 6B), at the same s.c.
location in the paw as the antibody injection, resulted in virtually no increase in paw
mechano-sensitivity. By comparison, pre-injections of the same amount of naïve serum-
derived IgG did not diminish the hypersensitivity from mPro-NGF (Fig. 6 C) or from NGF
(not shown).
3.6. The myristoylated pseudosubstrate inhibitor of aPKCs (mPSI) suppresses NGF-
induced hyperalgesia
Previously published electrophysiological studies of isolated sensory neurons have shown
that NGF-induced hyperexcitability depends on the nSMase > ceramide > S-1-P pathways,
with an essential downstream role of aPKCs, specifically PKMζ (Zhang et al., 2002, 2006,
2012; Nicol and Vasko, 2007). To determine whether aPKCs were involved in the local
effects of NGF, we pre-treated rats peripherally with mPSI, a cell permeant inhibitor acting
non-selectively on all aPKCs (Eicholtz et al., 1993; Thiam et al., 1999; Harishchandran and
Nagaraj, 2005; Moscat et al., 2006). Edema of the paw followed acutely after mPSI
injection, possibly due to its actions on vascular targets unrelated to aPKCs (Krotova et al.,
2006), and this necessitated a delay before the injection of NGF. Therefore, this inhibitor
was injected subcutaneously (40 µg/20 µl) into the plantar hind paw 24h before the injection
of NGF. Pre-injection of mPSI alone did not increase the responsiveness to mechanical
stimulation tested 24h later, the small changes being the same as from vehicle injection (Fig.
7A), and by then there was no edema. Locally administered mPSI strongly suppressed the
development of mechanical hyperalgesia from NGF injected into the same plantar area
(n=16, Fig. 7B, compare to Figures 1, Fig. 7D). A scrambled version of mPSI did not affect
the hypersensitivity from NGF (Fig. 7C), showing the selectivity of this inhibitor for its
aPKC inhibitory function (Krotova et al., 2006). In cohort-matched control experiments, a
robust hyper-responsiveness was observed at 0.5–24h after NGF injection in the control
group of rats, which had been pre-injected with intraplantar vehicle (PBS) 24h before NGF
(n=13, Fig 7D).
As with NGF, intraplantar mPSI blocked the acute hyperalgesia resulting from injection of
C2-ceramide into the paw (Fig. 7E). From 0.5 to 3h after C2-ceramide (20µg/10 µL)
injection into the paw, the responsiveness was unchanged from the baseline values (n=12),
contrasting with the enhanced sensitivity caused by this dose of C2-ceramide in naive rats
(cf. Fig. 2).
4.0. DISCUSSION
The mechanism of NGF-induced mechanical hyperalgesia is not completely known. NGF
initiates a variety of intracellular signals through activation of its two receptors, TrkA, with
a higher NGF affinity and slower dissociation (respectively, Kd ~10−11M, t1/2 ~ 10 min),
and a broadly selective neurotrophin receptor, p75NTR, having a lower affinity and faster
dissociation for NGF (Kd ~10−9M, t1/2 ~ 3 sec) (Meakin and Shooter, 1992). Both receptors
are expressed on sensory neurons and are assumed to be activated by relatively high
concentrations of NGF either released endogenously during inflammation, or administered
exogenously (Woolf, 1996; Woolf et al., 1996; Nicol and Vasko, 2007). We tested the
hypothesis that activation of the p75NTR signaling cascade that has been shown to sensitize
isolated peripheral nociceptive neurons (Zhang et al., 2002; Zhang and Nicol, 2004; Zhang
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et al., 2012) contributes to the sensitization of mechanical responsiveness by NGF in adult
rats in vivo. Our findings show a rapidly developing tactile hypersensitivity, present at 1 h
and persisting for at least 24h after hindpaw injection of 500 ng of NGF. Injection of the
p75NTR-selective homologue Pro-NGF, which had been mutated to mPro-NGF in order to
prevent the hydrolytic cleavage that frees mature NGF (Pagadala et al., 2006), produced an
identical hypersensitivity. Direct binding studies show that Pro-NGF binds with ~5-fold
higher affinity to p75NTR than to TrkA receptors (Lee et al., 2001; Nykjaer et al., 2004),
although the predominant pathway in any action will depend on the relative levels of
expression of the two receptors (Masoudi et al., 2009) and early evidence suggests that
interactions between the two receptors may alter their activities (Benedetti et al., 1993).
Importantly, paw injection of an antibody directed against the rat p75NTR (Weskamp and
Reichardt, 1991) prevented tactile hypersensitivity from either NGF or mutant Pro-NGF.
This antibody showed a large selectivity for the p75NTR based on direct NGF binding
studies and on their ineffectiveness in suppressing neuron survival and neurite outgrowth
that are known to be mediated by Trk receptors (Fariñas et al., 1998). Inhibition of NGF-
and mPro-NGF induced hyperalgesia by this antibody is consistent with an earlier report
wherein treatment with the same antibody prevented the NGF-induced increase in
excitability in isolated sensory neurons (Zhang and Nicol, 2004).
In addition, our results demonstrate that NGF/p75NTR – mediated hypersensitivity results
from activation of a neutral sphingomyelinase, can be recapitulated by a membrane-
permeant ceramide analogue, albeit only briefly compared to that of NGF, and, lastly, a key
downstream effector is an atypical PKC in the periphery NGF-induced mechanical
hypersensitivity in adult rats develops after a single systemic injection (1 µg/gm, s.c.) with a
rapid (0–7h) and a slow (8–30h) phase (Lewin et al., 1993). The authors suggested that the
delayed mechanical hypersensitivity in adult rats results from central changes, perhaps due
to up-regulation of peptides in the peripheral
NGF-responsive sensory neurons, where the internalized NGF-TrkA complex in the
periphery could be transported to central terminals within hours. Thermal hypersensitivity
was attributed to both peripheral and central neuron sensitization. NGF’s involvement in
prolonged inflammatory hyperalgesia, after injection of Complete Freund’s Adjuvant,
appears to require both sensory neurons and mast cells (Woolf et al., 1996), both of which
express TrkA receptors. Consistent with our results described above, intradermal injection of
NGF (1µg) into the dorsum of the paw after just 10 min, resulted in tactile hypersensitivity
that reached its peak change by 3h and lasted for several days (Malik-Hall et al., 2005).
Most recently it has been shown that single intraplantar injections of NGF (0.3–5 µg/paw)
reduced the mechanical withdrawal threshold maximally by 50–70 % after 1hr, which only
slowly reversed over several weeks (Mills et al., 2013).
Previous publications present contradictory findings about the roles of TrkA vs. p75NTR in
pain sensitization. Most publications support an essential role of the TrkA receptor (Mantyh
et al., 2011). Mutated mice lacking p75NTR still develop mechanical and thermal
hyperalgesia after systemic NGF delivery (Bergmann et al., 1998), suggesting that TrkA
plays the dominant role. However, these knock-out mice have higher thresholds for acute
nocifensive responses to cutaneous thermal and mechanical stimuli and show significant
reductions in the density of epidermal neurites (Bergmann et al., 1997). Differences in the
distribution of DRG cell sizes between p75NTR −/− mice and the wild-type+/+ controls were
modest, and there was no difference in their neurochemical profiles (Bergmann et al., 1997).
Others, however, have reported a marked reduction of both peptide-containing neurites in
the skin and thermal sensitivity in p75NTR knock-out mice (Lee et al., 1992). Also in support
of TrkA involvement, intrathecal delivery of anti-sense oligodeoxynucleotides targeted to
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TrkA decreased TrkA protein in peripheral nerve and prevented NGF-induced mechanical
hyperalgesia (Malik-Hall et al., 2005).
In contrast, other studies suggest that the p75NTR plays a key role in pain. Inflammation
resulting from CFA injection into the rat wrist joint induced an upregulation of p75NTR
immunoreactivity, and local injections of blocking antibodies against the p75NTR reduced
CFA-induced mechano-hyperalgesia (Iwakura et al., 2010). Similarly, intraplantar injections
of CFA, NGF or Pro-NGF caused thermal hypersensitivity, and also increased the
expression of CGRP in primary sensory neurons, both changes being prevented by the anti-
p75 NTR blocking antibody (Watanabe et al., 2008). Signaling through the sphingomyelin
pathway is known to be activated by the low-affinity p75NTR, resulting in the liberation of
ceramide (Dobrowsky et al., 1994). Consistent with this idea, C2-ceramide injected into the
paw induces mechano-hyperalgesia that is mimicked by injection of TNF-α (Woolf et al.,
1997), an effect that was blocked by the nSMase inhibitor GW4869 (Joseph and Levine,
2004). Recent findings further show that intraplantar injection of C2-ceramide produced
thermal hyperalgesia that peaked 1h post-injection, as well as increased levels of TNF-α
(Doyle et al., 2011a,b).
There is compelling evidence that NGF acts directly on sensory neurons. Capsaicin-evoked
currents through TRPV1 receptors (Shu and Mendell, 1999, 2001), were enhanced via
activation of TrkA (Galoyan et al,, 2003; Zhu and Oxford, 2007). NGF-induced activation
and up-regulation of TRPV1 (Winston et al., 2001; Zhang et al., 2005), and this receptor/
channel’s transport to peripheral C-fiber terminals of adult rat DRG neurons contributes to
the maintenance of inflammatory heat hypersensitivity (Ji et al., 2002). In capsaicin-
sensitive, small-diameter DRG neurons isolated from adult rats, both NGF and C2-ceramide
acutely increased firing of action potentials (AP) as a result of the rapid augmentation of a
tetrodotoxin-resistant sodium current and suppression of a delayed rectifier-type potassium
current (Zhang et al., 2002); both actions appear to involve the p75NTR receptor. This effect
from NGF, but not the identical one from C2-ceramide, was completely prevented by
pretreatment with the same p75NTR blocking antibody used in the current studies (Zhang
and Nicol, 2004). Furthermore, inhibitors of tyrosine kinase receptors failed to affect the
increased AP firing produced by either NGF or BDNF (Zhang et al., 2008). Involvement of
the sphingomyelin signaling pathway is evident in the NGF-induced augmentation of AP
firing by its strong inhibition by glutathione, a cell-permeant inhibitor of nSMase, as also
shown in our present in vivo study. This increase in excitability could be mimicked by
intracellular perfusion with bacterial SMase, simulating the release of native ceramide by
endogenous enzymes. Exogenous C2-ceramide enhanced the number of evoked APs, despite
the presence of glutathione and NGF, indicating that ceramide’s sensitizing actions lay
downstream of NGF (Zhang et al., 2002), identical to the interactions shown here in vivo.
Moreover, sphingosine-1-phosphate, a product of intracellular metabolism of ceramide by
sphingosine kinase, acted as a second messenger in augmenting neuronal excitability (Zhang
et al., 2006).
In the current work both intraplantar NGF and C2-ceramide induced mechanical
hypersensitivity. However, NGF - evoked hyperalgesia persisted at least for 24h (also see
Mills et al., 2013) whereas that from a single C2-ceramide injection had resolved by 2h.
Multiple sequential injections of this dose of C2-ceramide extended the hypersensitivity
after the last dose, but not for more than a few hours, still very brief compared to NGF. This
difference in the duration of hypersensitivity may be explained by the different abilities of
the two agents to persistently activate the common pathway. In isolated cells the two
compounds cause essentially identical changes in excitability and its underlying ion currents
(Zhang et al., 2002). But the C2-analogue of ceramide might be quite differently disposed of
in the rat than the longer fatty acyl chain ceramides that are liberated in vivo by nSMase;
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these ceramides may be bound to hydrophobic regions of membranes or proteins and thus
less mobile for diffusion and less amenable to degradative enzymes (Liu and Hannun, 1997;
Liu et al., 1998). Furthermore, other cells near the cutaneous injection site, e.g.,
keratinocytes, might also respond to NGF and to ceramide, leading to activation of pathways
that are absent from isolated sensory neurons.
Two different nSMase inhibitors appeared effective against the acute hyperalgesic actions of
NGF. Brief (15 min) pre-treatment with GSH, a selective inhibitor of nSMase activation
(Liu and Hannun, 1997; Liu et al., 1998), prevented the acute NGF-induced hyperalgesia,
measured 1.5h later, but did not affect mechanical hypersensitivity measured the next day.
This finding suggests that there is a limited time during which GSH’s inhibitory actions are
effective, implying that the period of p75NTR-induced nSMase activation continues after the
readily oxidized GSH has been exhausted or removed from the paw. To test the hypothesis
of limited time of protection we injected a high concentration of GSH 1.5h before NGF
(which was also co-injected with GSH). This earlier delivery of GSH failed to suppress the
NGF-induced tactile hyperalgesia, showing that protection by GSH is indeed a short-lived
phenomenon.
The cell-permeant non-competitive nSmase inhibitor GW4869, injected once shortly before
NGF, also prevented the NGF-induced hyperalgesia at 0.5–1.5h, but not on the next day.
Here, using a more stable inhibitor than GSH (Luberto et al., 2002), a preventive effect of
nSMase inhibition also lasted only a short time. It is plausible that the inhibitor could have
been removed from the paw by the next day, which may explain the lack of GW4869 anti-
hyperalgesic actions at 23h post NGF. However, GW4869 when injected 1h after NGF also
appeared to be completely ineffective against the previously developed hyperalgesia. These
results imply that the liberation of ceramide by nSMase contributes to the induction rather
than the maintenance of mechanical hypersensitivity in rat plantar skin, wherein the
downstream effect of ceramide, once initiated, leads to continuous functioning of
intracellular machinery to provide a hyperalgesic state. The short term preventive actions of
peripheral nSMase inhibitors against NGF-induced hypersensitivity along with the acute
hyperalgesic actions of exogenous C2-ceramide suggest an involvement of different
signaling events, possibly through different sensory neuron sub-types innervating different
spinal targets, to provide a long-lasting hyper-responsiveness from NGF (Kobayashi et al.,
2012).
PKCs are profoundly important for cellular responses to extracellular stimulation (Gallegos
and Newton, 2008; Gould and Newton, 2008; Newton, 2009) where the atypical PKCs seem
to have a specialized role in mediating long-term changes (Moscat and Diaz-Meco, 2000;
Hirai and Chida, 2003). Recent studies, either using a pseudosubstrate inhibitor targeting all
aPKCs, mPSI (ZIP), or specifically knocking down PKMζ by siRNA, identified this
isozyme of PKC as the critical kinase in the NGF-p75NTR pathway driving sensitization of
isolated sensory neurons (Zhang et al., 2012). Although the current results do not identify
the specific aPKC that is involved, our experiments show that one of these isozymes appears
to be essential in the periphery for hypersensitivity mediated through the p75NTR.
Atypical PKCs are claimed by some to be essential contributors supporting chronic
hyperalgesia after nerve injury (King et al. 2012; see Price and Ghosh, 2013). Recruited by
NGF to enhance the excitability of isolated rat sensory neurons (Zhang et al., 2012), PKMζ
also appears to be essential for the development and persistence of a sensitized state in the
dorsal horn (Laferriere et al., 2011; Marchand et al., 2011; Asiedu et al., 2011). These
papers report an elevation of activated and total aPKCs, especially PKMζ, in the dorsal horn
after inflammation, and a reduction of inflammation-induced hyperalgesia by chemical
inhibition of spinal PKMζ. The current paper, and related previous in vitro studies (Zhang et
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al., 2012), suggest that peripheral aPKCs may also contribute to the relatively long lasting
changes in hyper-excitability that subserve prolonged hyperalgesia after NGF.
Figure 8 presents a scheme that summarizes this work. Key mediators of the p75NTR
signaling pathway contribute to mechanical hyperalgesia induced by NGF, which is
consistent with their sensitizing effects demonstrated in the isolated nociceptive DRG
neurons. However, accumulating evidence on potential cross-regulation and signaling
interactions between p75NTR and TrkA pathways in nociceptive sensory neurons, e.g.,
common activation of phosphatidylinositol 3-kinase (PI3K) (reviewed by Huang and
Reichardt, 2003), or common up-regulation of substance P synthesis by both pathways
(Skoff and Adler, 2006), indicate that signaling from both NGF-binding receptors could be
involved in mechanical sensitization. The results reported here do not eliminate a role for the
TrkA receptor in acute pain processing, but our findings do establish a greater role for
p75NTR and its downstream signaling cascade than was previously recognized.
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Abbreviations
p75NTR p75 neurotrophin receptor
nSMase neutral sphingomyelinase
aPKC atypical PKC
DMSO dimethyl sulfoxide
DRG dorsal root ganglia
MAPK Mitogen activated protein kinase
COX2 Cyclo-oxygenase 2
PLC phospholipase C
PGE2 prostaglandin E2
VFH von Frey hair
NGF nerve growth factor
C2-ceramide N-acetyl sphingosine
GSH glutathione
PKCζ/PKMζ protein-kinase C zeta or protein-kinase M zeta
TrkA tyrosine kinase receptor A
IPSI ipsilateral paw
CLP contralateral paw
s.c. subcutaneously
mPSI myristoylated pseudosubstrate inhibitor
PBS phosphate buffered saline
ODN oligodeoxyribonucleotides
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TRPV1 transient receptor potential cation channel subfamily V member 1
AP action potential
siRNA small interfering RNA
PI3K phosphatidylinositol 3-kinase
BDNF brain derived neurotrophic factor
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Highlights
Subcutaneously injected NGF induces tactile hyperalgesia for more than 24 hours.
A p75NTR – selective agonist, Pro-NGF, causes the same effect.
A blocking antibody of the p75NTR prevents the hyperalgesia from NGF and Pro-NGF.
Intermediates of the neutral sphingomyelinase pathway simulate this effect of NGF.
An inhibitor of aPKCs injected beforehand in the same paw suppresses NGF’s effects.
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Figure 1.
Mechanical hyperalgesia induced by NGF. (A) Paw withdrawal frequency in response to
stimulation with 10g and 15g VFH was enhanced following subcutaneous injection of 500
ng/10 µL NGF into the rat plantar hind paw (n=7). *P<0.05 vs. baseline values (Friedman
test followed by Dunn's post hoc test), #P<0.05, ##P<0.001 vs. CLP (two-tailed Mann-
Whitney test). (B) No changes in mechanical responsiveness occurred in the contralateral
plantar hind paw following local administration of NGF.
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Figure 2.
Mechanical hyperalgesia induced by local C2-ceramide. (A) C2-ceramide (20 µg/10 µL)
injected s.c. into the rat plantar hind paw caused an acute increase in responsiveness to
stimulation with low and medium forces (4g, 10g) (n=9). **P<0.01 vs. baseline, ^P<0.05 vs.
responses at 2h (Friedman test followed by Dunn's post hoc test), ###P<0.005 compared to
the contralateral values (two-tailed Mann-Whitney test); for allodynia: (+) p=0.0450
(Friedman test), without significant difference between rank sum means (Dunn's post hoc
test). (B) In comparison, significantly elevated ipsilateral responsiveness to stimulation by
all 3 forces was observed at 2h after the 3rd of 3 consecutive s.c. injections of C2-ceramide
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(20 µg/10 µl) given every 75min into the same plantar spot (n=12). **P< 0.01, **P< 0.005
(Wilcoxon matched pairs test, two-tailed).
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Figure 3.
Glutathione (GSH), an inhibitor of nSMase, prevented the acute hyperalgesia induced by
NGF. (A) GSH (1.8 µmoles/paw total dose), when pre-injected (120 mM, 10 µL) 15 min
before and then co-injected (60 mM, 10 µL) with NGF (500 ng/10 µL), prevented
hyperalgesia measured at 1–1.5h, but did not that measured on the next day (n=8). *P<0.05
vs. baseline IPSI (Friedman test followed by Dunn's post hoc test). (B) When glutathione
(1.8 µmoles/ paw total dose) was injected (120 mM, 10 µL) s.c. intraplantar 1.5h before and
then co-injected (60 mM, 10 µL) with NGF (500 ng/10 µl) the acute stage of hyperalgesia
Khodorova et al. Page 19
Neuroscience. Author manuscript; available in PMC 2014 December 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
still occurred (n=4, p=0.0324 for both 4g and 15g forces (Friedman test); #P<0.05 compared
to the CLP responses (two-tailed Mann-Whitney test)
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Figure 4.
A short-lasting preventive effect of GW4869 against NGF-induced hyperalgesia. (A) A cell-
permeant non-competitive, nSMase inhibitor, GW4869 (2 mM, 10 µL; dose 20 nmoles/
plantar paw), injected 17 min prior to NGF (500 ng/10 µl), prevented acute hyperalgesia, at
0.5–1.5h, but not the later hyperalgesia, at 23h after injection (n=8). (B) Hyperalgesic
actions of NGF in controls, where vehicle (DMSO, 10 µL) injection preceded NGF (n=8).
(C) GW4869 (2 mM, 10 µL; dose 20 nmoles/plantar paw) was ineffective against NGF-
induced hyperalgesia when it was injected 1h after NGF (500 ng/10 µL) (n=7). Note
significantly increased responses at 35–50min after NGF (injection into naïve paw), at 2h
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(=35–50min post GW4869; for 15g as compared with CLP, Mann-Whitney test), at 3h
(=1.5h post GW4869), and at 22–23h (=ca. 22h post GW4869). *P<0.05, **P<0.01 vs.
baseline (Friedman test followed by Dunn's post hoc test), #P<0.05, ##P<0.005, ###P<0.001
compared to the CLP values (two-tailed Mann-Whitney test).
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Figure 5.
Mechanical ipsilateral hyperalgesia is induced by mutated, protease-resistant Pro-NGF. Paw
withdrawal frequency in response to stimulation with 10g and 15g VFH was enhanced
following s.c. injection of mPro-NGF ( 500 ng/10 µL) into the rat plantar hind paw (n=8).
*P<0.05, **P<0.01 vs. baseline values (Friedman test followed by Dunn's post hoc
test), #P<0.05, ##P<0.01 vs. baseline values (Wilcoxon matched pairs test, two-tailed).
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Figure 6.
A polyclonal antibody to p75NTR prevented mechanical hyperalgesia induced by NGF and
mProNGF. (A) When pre-injected (20 µL) into the paw 4h before NGF (500 ng/10 µl), the
antibody prevented any significant hyperalgesia at 0.5h-21h (n=6). (B) A similar inhibition
occurred when the antibody was injected 4h before mPro-NGF (500 ng/10 µL) (n=6).
Significant elevation of response was found only for the 10g force at 2h after mPro-NGF
injection. #P<0.05 vs. baseline-after-antibody values (Wilcoxon matched pairs test, two-
tailed), and +P<0.05 vs. baseline-after-antibody values and vs. 21h values for 3 groups
comparison: Bsl a.ab., 2h, 21h (Friedman test followed by Dunn's post hoc test). Bsl a.ab. =
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2.5h after ab.p75 injection. (C) In controls, where IgG (20 µL) from naïve serum was
injected 4h prior to mPro-NGF, hyperalgesia was fully present(n=6; compare with Fig 5).
Bsl a.IgG=2.5h after IgG injection.
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Figure 7.
Local pre-treatment with myristoylated pseudosubstrate inhibitor of atypical PKCs
decreased hyperalgesia from NGF and C2-ceramide. For all panels the inhibitor (40 µg /20
µl) was injected subcutaneously into the plantar hind paw 24h before the intraplantar
injection of the algogens. (A) mPSI alone did not change the plantar hind paw
responsiveness to mechanical stimulation, when tested at 24h after injection into naïve rats.
(B) NGF injected into the plantar area after mPSI induced a much smaller than usual
hyperalgesia (n=16): significant changes in responses were found only for 15g force
(p=0.0489, Friedman Test for 5 groups; no significance by Dunn's post hoc test). However,
even for 15g, P>0.05 was found when the test was applied to 4 same day-groups, excluding
24h time point responses. Analysis by Mann Whitney test revealed a significant difference
for comparisons with corresponding baseline values only for 4g and 15g, at 3h and 24h time
points, respectively. (C) Injection into the plantar hind paw of scrambled mPSI(40 µg /20
µl), which lacks inhibitory action on aPKCs, 24h before the intraplantar injection of NGF,
neither prevented, nor decreased hyperalgesia from NGF (500 ng/10 µl) (n=8). *P<0.05,
**P<0.01, ***P<0.001 vs. baseline (Friedman test, 5 groups, followed by Dunn's post hoc
test); #P<0.05, ##P<0.01 vs. baseline (two-tailed Wilcoxon test). (D) Vehicle control:
pronounced hyperalgesia at 0.5–24h after NGF injection was observed in rats pre-injected
with vehicle (PBS) into the same plantar area 24h before (n=13). *P<0.05, **P<0.01 vs.
baseline (Friedman test followed by Dunn's post hoc test). Some enhancement was revealed
for responses to 4 g p=0.0032 (Friedman test, 5 groups), however, no significance was found
by Dunn's post hoc test. +P<0.05, ++P<0.01 compared to baseline values (two-tailed
Wilcoxon test). (E) mPSI (40ug/20uL) injected i.pl. prevented mechanical hyperalgesia
induced by C2-ceramide (20ug/10uL) (n=9).
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Figure 8.
The intracellular signaling pathway downstream of p75NTR which leads to mechanical
hyperalgesia from NGF in rat plantar hind paw, and a summary of the antihyperalgesic
effects of the treatments used in the current work. NGF induced a long-lasting hyperalgesia
(up to 24h), while the effect from a single injection of C2-ceramide was brief (<2h). Both
inhibitors of nSMase, GSH (at a high total dose) and GW4869, prevented the acute
hyperalgesia from NGF. A post facto application of GW4869, however, failed to reverse
NGF-induced hyperalgesia. Intraplantar pre-treatment with myristoylated pseudosubstrate
inhibitor of aPKCs, mPSI, (1 day before) strongly decreased the hyperalgesic actions of
NGF. Key: (+) - hyperalgesia was observed; (--) - hyperalgesia was not observed; nt – not
tested.
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